Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 47Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunction, Physiological 1Prostatic Intraepithelial Neoplasia 1Prostate Adenocarcinoma 1Primary Dysautonomias 1Neoplasm Metastasis 1Kidney Diseases 1Infertility 1Hypertension 1Castration-resistant Prostate Cancer 1

Interventions

enzalutamide 5abiraterone 2Radiotherapy 2Metastasectomy 2Abiraterone Acetate 2testosterone enanthate 1radium Ra 223 dichloride 1pembrolizumab 1disitamab vedotin 1dactolisib 1VT-464 1Radium-223 1Radiosurgery 1Prednisone 1NVP-BKM120 1Ketoconazole 1Injections 1Hydrocortisone 1Flutamide 1Cyclophosphamide 1Crizotinib 1Control Groups 1Carboplatin 1Calcitriol 1Blood Specimen Collection 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castration-resistant Prostate Cancer × Flutamide × Genitourinary × Clear all
NCT02346578 2021-09-16

Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.

Osaka City University

Phase 2 Completed
104 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡